Merck vaccine trial delayed
Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...
Shares of Merck & Co. Inc. MRK rallied 2.08% to $89.50 Friday, on what proved to be an all-around rough trading session for ...
SAN DIEGO, CA / ACCESS Newswire / February 20, 2025 / Robbins LLP reminds stockholders that a class action was filed on ...
Lawsuits surrounding Merck's HPV vaccine Gardasil have been piling up for years now, but they've garnered increased public ...
Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech Epitopea to identify previously secret ...
Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE: MRK) between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class ...
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $112.46, a high ...
Merck KGaA said it’s in advanced talks to purchase SpringWorks Therapeutics Inc., sending shares of the US cancer and rare ...
Eliquis, a blood thinner marketed in partnership with Bristol Myers Squibb, is Pfizer's largest revenue stream at the moment.
Germany’s Merck KGaA is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical ...
Germany's Merck KGaA said on Tuesday its lab equipment division and its pharmaceuticals division would be under new ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results